T 0872/13 (Factor VII Glycoforms/NOVO NORDISK) vom 28.08.2018
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2018:T087213.20180828
- Datum der Entscheidung
- 28. August 2018
- Aktenzeichen
- T 0872/13
- Online am
- 26. Februar 2019
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 05766825.3
- IPC-Klasse
- C07K 14/745C12P 21/00C12N 9/64
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- O-LINKED GLYCOFORMS OF FACTOR VII AND METHOD TO MANUFACTURE THEM
- Name des Antragstellers
- Novo Nordisk Health Care AG
- Name des Einsprechenden
- Strawman Limited
- Kammer
- 3.3.01
- Leitsatz
- -
- Relevante Rechtsnormen
- Rules of procedure of the Boards of Appeal Art 15(3)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13European Patent Convention R 115(2)European Patent Convention Art 54(2)European Patent Convention Art 100(a)European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 84European Patent Convention Art 83European Patent Convention Art 56
- Schlagwörter
- Oral proceedings - held in absence of appellant
Acceleration of proceedings - (no)
Late-filed evidence - submitted with the statement of grounds of appeal or reply thereto: admitted
Late-filed evidence - submitted at a late stage of appeal proceedings and complex: not admitted
Novelty - implicit disclosure (yes/no)
Amendments - allowable (yes)
Claims - clarity after amendment (yes)
Sufficiency of disclosure - (yes)
Inventive step - (yes) - Orientierungssatz
- -
- Zitierende Akten
- T 1114/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the
order to maintain the patent as amended in the following
version:
- claims 1 to 6 filed as auxiliary request 3 with the letter dated 9 September 2013,
- description: pages 2, 2a, 3 to 13 filed at the oral proceedings of 28 August 2018 and pages 14 to 20 of the patent specification, and
- drawings: figures 1 to 8b of the patent specification.